J Gynecol Oncol | Volume 4, Issue 4 | Mini Review | Open Access

PIK3R2 is an Oncogene and a Predictor of Response to Tyrosine Kinase Inhibitors in Ovarian Cancer

Zhang Shibo and Cheung Lydia WT^*

Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong

^*Correspondance to: Cheung Lydia WT 

Fulltext PDF

Abstract

The p85 regulatory subunits of the Phosphoinositide 3-Kinase (PI3K), which include p85α and p85β, interact with the Receptor Tyrosine Kinases (RTKs) and the p110 catalytic subunits for PI3K pathway activation. High levels of PIK3R2/p85β correlate with worse patient survival in ovarian cancer. Investigations are warranted to understand the regulatory role and pathogenic role of p85β in pathway activation and cancer development, respectively. Recently, we have revealed the molecular mechanisms through which p85β induces ovarian tumorigenesis. Remarkably, these oncogenic mechanisms create exploitable vulnerabilities to targeting of the RTKs.

Keywords:

Citation:

Zhang S, Cheung Lydia WT. PIK3R2 is an Oncogene and a Predictor of Response to Tyrosine Kinase Inhibitors in Ovarian Cancer. J Gynecol Oncol. 2021; 4(4): 1066.